<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948857</url>
  </required_header>
  <id_info>
    <org_study_id>092508-01</org_study_id>
    <nct_id>NCT00948857</nct_id>
  </id_info>
  <brief_title>Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)</brief_title>
  <acronym>DHEAFert2</acronym>
  <official_title>A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Premature Ovarian Failure (POF).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David H. Barad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for Human Reproduction</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The experimental focus of this project is on the interaction of DHEA treatment on pregnancy
      in women with open tubes, fertile male partners and evidence of premature ovarian failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment:

        -  New patients presenting for Donor egg cycles

        -  Possible print, magazine or Radio advertisement

      Experimental plan:

        1. Informed consent

        2. Baseline studies

             -  Antral follicle counts

             -  Serum FSH, LH, E2, Prog, DHEA, DHEAS, testosterone, AMH, Fragile X

        3. Randomization

             -  Group A: DHEA (25 mg three times per day)

             -  Group B: Placebo

        4. Monitoring during treatment

             -  All participants will have:

             -  USG for follicle measurement

             -  Repeat serum, FSH, E2, DHEA, DHEAS, testosterone, AMH monthly during treatment.

             -  Physical examination

             -  Completion of study questionnaire regarding possible androgen effects of treatment

        5. Analysis plan:

             -  Primary Outcome

             -  Pregnancy

             -  Pregnancy rates will be compared using logistic regression with age and
                pre-treatment AMH as covariates.

             -  Secondary Outcomes

             -  Endocrine Factors

             -  Androgen side effects

             -  Primary analysis. We will perform a factorial ANOVA for the two pretreatment
                factors DHEA and Placebo. Baseline AMH and age as main covariates

             -  Secondary analysis.

             -  Examine rate of change of estradiol and other endocrine response over the four
                cycles of treatment

             -  Compare antral follicle counts across cycles between groups

             -  Compare possible androgen related effects

             -  Power considerations:

             -  Power assumptions: alpha 0.05; 80% power

      Spontaneous Pregnancy rate for POF is less than 1% per 3 months Intervention will improve
      pregnancy rate to 10% per 3 months. Patients will be treated for 3 cycles. Require 100
      patients to complete treatment in each group. Allow for 20% dropout will need 120 patients
      randomized to each group

        -  Randomization:

      Randomization will be by permuted blocks in order to maintain an even distribution among the
      groups (because of the small numbers of participants)

        -  Human subjects issues

        -  Potential risks associated with DHEA use

        -  Potential risk of delay of treatment for 3 months and possible natural continued loss of
           fertility

        -  Informed consent issues
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment.
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Live Birth</measure>
    <time_frame>9 months</time_frame>
    <description>Live Birth outcome compared between DHEA active treatment and Placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endocrine Effects</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androgen Side Effects</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>DHEA active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dehydroepiandrosterone 25 mg tid po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHEA Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dehydroepiandrosterone</intervention_name>
    <description>25 mg PO TID</description>
    <arm_group_label>DHEA active treatment</arm_group_label>
    <other_name>DHEA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Blinded placebo</description>
    <arm_group_label>DHEA Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;= 1 year of infertility

          -  &gt;21 and &lt;40 years old

          -  Normal HSG

          -  Normal Semen analysis (Count &gt;= 20 million/ motility &gt; 50%/ Kruger morph &gt; 14%.

          -  Absent menses

          -  Willingness to sign informed consent for study randomization

          -  Willingness to participate in 3 months of treatment.

        Exclusion Criteria:

          -  Abnormal semen analysis

          -  Abnormal HSG

          -  Medical condition that would contraindicate pregnancy, ovulation induction or general
             anesthesia

          -  Family history of significant genetic disease, or factor V leiden thrombophilia

          -  Inability to present for monitoring visits

          -  Inability to follow medication instruction

          -  Desire to undergo other fertility treatments before completing three months of this
             trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Barad, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Reproduction</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Gleicher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Human Reproduction</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Reproduction</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.centerforhumanreprod.com/</url>
    <description>Center for Human Reproduction</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2009</study_first_posted>
  <results_first_submitted>August 2, 2012</results_first_submitted>
  <results_first_submitted_qc>August 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2012</results_first_posted>
  <last_update_submitted>September 4, 2012</last_update_submitted>
  <last_update_submitted_qc>September 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Center for Human Reproduction</investigator_affiliation>
    <investigator_full_name>David H. Barad</investigator_full_name>
    <investigator_title>Director of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>DHEA</keyword>
  <keyword>POF</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Ovarian Failure</keyword>
  <keyword>Otherwise Unexplained infertility</keyword>
  <keyword>Ovarian aging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dehydroepiandrosterone 25 mg Tid po</title>
          <description>Dehydroepiandrosterone 25 mg tid po</description>
        </group>
        <group group_id="P2">
          <title>Blinded Placebo</title>
          <description>Blinded placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">3 completed and 1 dropped out.</participants>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dehydroepiandrosterone 25 mg Tid po</title>
          <description>Dehydroepiandrosterone 25 mg tid po</description>
        </group>
        <group group_id="B2">
          <title>Blinded Placebo</title>
          <description>Blinded placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="3"/>
                    <measurement group_id="B2" value="38" spread="3"/>
                    <measurement group_id="B3" value="38" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Live Birth</title>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endocrine Effects</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Androgen Side Effects</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pregnancy</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Live Birth</title>
        <description>Live Birth outcome compared between DHEA active treatment and Placebo</description>
        <time_frame>9 months</time_frame>
        <population>This study was closed for futility because of difficulty finding patients willing to undergo randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>DHEA</title>
            <description>Dehydroepiandrosterone 25 mg tid po</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Blinded placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth</title>
          <description>Live Birth outcome compared between DHEA active treatment and Placebo</description>
          <population>This study was closed for futility because of difficulty finding patients willing to undergo randomization.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dehydroepiandrosterone 25 mg Tid po</title>
          <description>Dehydroepiandrosterone 25 mg tid po</description>
        </group>
        <group group_id="E2">
          <title>Blinded Placebo</title>
          <description>Blinded placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Termination due to lack of consenting participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Norbert Gleicher</name_or_title>
      <organization>Center for Human Reproduction</organization>
      <phone>212-994-4400</phone>
      <email>ngleicher@thechr.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

